# Skin & Aesthetics Peptide FAQ — GHK-Cu and GLOW — Peptide Bounce Balm

> Frequently asked questions about GHK-Cu and the GLOW research blend — answered from the peer-reviewed literature, with numbered citations.

Direct, citation-anchored answers to the questions readers most often bring to these two skin and aesthetics peptides.

## What does a GHK-Cu peptide do?

GHK-Cu does two related things: it ferries copper into tissue, and it uses that delivery to signal cells to rebuild collagen and elastin scaffolding. At picomolar to nanomolar concentrations it directly stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans, and the structural proteoglycan decorin, while rebalancing the enzymes that break down matrix against their inhibitors [4]. It also stimulates production of angiogenic factors (VEGF, FGF-2) and nerve growth factor while suppressing pro-inflammatory signals including TGF-beta-1 and TNF-alpha [6]. Its best-documented human applications are topical — in small trials it measurably outperformed vitamin C and retinoic acid on collagen production and signs of skin aging [1][4].

## What is GHK-Cu and how does it work?

GHK-Cu is the copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine. The same GHK sequence exists inside type I collagen, which is why researchers hypothesize that GHK-Cu released from degrading collagen signals local tissue to initiate repair [4]. It works primarily as a copper chaperone (delivering copper to copper-dependent enzymes like lysyl oxidase, which cross-links collagen and elastin) and as a low-concentration signaling molecule that activates fibroblast repair programs. A gene-expression analysis showed it shifts roughly 31.2% of human genes at a 50%-or-greater change threshold, with the largest effects on ubiquitin-proteasome, DNA-repair, and antioxidant pathways [2]. Copper coordination is required — the free GHK tripeptide without copper is a different molecule with different activity.

## Is GHK-Cu peptide really anti-aging?

There is a modest, real human signal, mostly from topical trials. GHK-Cu increased collagen production in about 70% of treated subjects versus 50% for vitamin C and 40% for retinoic acid in one comparison, and clinical reviews report placebo-controlled improvements in skin laxity, fine lines, and wrinkle depth [4]. A 6-month RCT of a GHK-containing combination formulation in 45 men with hair loss produced statistically significant hair-count gains over placebo, with no adverse events [3]. Two caveats temper that: the trials are small, and the widely circulated "~4,000 genes" anti-aging claim is an extrapolation from a verified figure of roughly 2,100 genes at the measured threshold [2]. Injectable or systemic anti-aging use is unapproved and unsupported by controlled human data.

## What is the difference between GHK and GHK-Cu?

GHK is the bare tripeptide glycyl-histidyl-lysine. GHK-Cu is that same tripeptide bound one-to-one to a copper(II) ion through the histidine imidazole and glycine amino groups. The distinction matters functionally: copper coordination is required for most of the reported bioactivities — collagen cross-linking, lysyl-oxidase activity, the antioxidant effect [4]. Studies on GHK and GHK-Cu are reporting on different molecules, but secondary sources frequently conflate them. When you see a collagen-stimulation claim, check whether the study used the copper chelate.

## What is GLOW peptide?

GLOW is a research-supplier and clinic-formulated blend of three peptides: GHK-Cu (copper tripeptide-1), BPC-157 (a 15-amino-acid gastric cytoprotective peptide), and TB-500 (the 7-amino-acid actin-binding fragment of thymosin beta-4). It is not a single defined drug, not FDA-approved, and not standardized across suppliers. The combination rationale is that the three constituents address tissue repair from complementary directions — matrix building, angiogenesis, and cell migration — but no controlled study has tested the blend as a unit. Its claimed benefits extrapolate from single-component research, most of which is in animals [8].

## What does the GLOW peptide do?

Based on the published science for its individual constituents: GHK-Cu signals fibroblasts to build collagen and elastin [4][6]; BPC-157 promotes new blood-vessel growth via upregulation of the VEGFR2 pathway [10]; and TB-500 carries the actin-binding motif of thymosin beta-4, associated with cell migration and anti-scarring activity. Community reports describe benefits including skin brightening, smoother texture, and faster wound healing — labeled as anecdotal, not clinical evidence, and never tied to a verified dose. A 2026 Sports Medicine review naming all three constituents concluded that human safety data for such unapproved blends are scarce and there is potential for serious harm [8].

## What does GLOW peptide have in it?

GLOW typically contains three research peptides: GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, MW ~402.9 Da), BPC-157 (sequence GEPPPGKPADDAGLV, MW ~1419 Da), and TB-500 (Ac-LKKTETQ, MW ~889 Da). A commonly cited research-label ratio is 10 mg BPC-157 / 50 mg GHK-Cu / 10 mg TB-500, though supplier formulations are not standardized. The three peptides are structurally dissimilar, clear at different rates, and have not been characterized as a co-formulated pharmacological entity.

## What peptides are in the GLOW blend?

The three constituents are GHK-Cu, BPC-157, and TB-500. GHK-Cu is the copper tripeptide that gives the blend its skin and matrix-building rationale and the most human evidence of the three. BPC-157 is a synthetic gastric pentadecapeptide studied mainly in rodent tissue-repair models; it should be considered investigational in humans, where only three small pilot studies exist [9]. TB-500 is the actin-binding heptapeptide fragment of thymosin beta-4 — it is banned in sport by WADA [8]. None of the three, and not the blend, has an FDA-approved therapeutic indication.

## Is GLOW peptide safe?

The honest answer is that long-term human safety of the blend is genuinely unknown. BPC-157's 2025 narrative review found only three small human pilots and concluded it should be treated as investigational [9]. TB-500's strongest human data come from full-length thymosin beta-4 (a Phase 1 study of 40 volunteers), not the shorter TB-500 fragment, and that gap in identity carries over to its safety record. The 2026 Sports Medicine review that names all three GLOW constituents explicitly states that rigorous human safety data for such unapproved peptides are scarce and there is potential for serious harm [8]. Community-reported adverse effects include injection-site stinging and redness, early fatigue, and occasional flushing — anecdotal, with no verified dose.

## Can GHK-Cu penetrate the skin on its own?

Poorly, through intact skin. GHK has a calculated log P of -2.24, meaning the intact stratum corneum is a significant barrier for the free peptide. A 2025 review of GHK as a topical anti-wrinkle compound confirms poor stratum-corneum permeability as the central delivery challenge and evaluates strategies including palmitoylation (which raises clogP to 1.14) and microneedle pretreatment (which increased GHK permeation to ~134 nmol versus none through intact skin) [1]. An ex vivo skin-penetration study did measure a dermal copper depot forming over 48 hours even from standard formulations [5], so some delivery occurs — but optimizing it is an active area of formulation research, and claims based on in vitro fibroblast work don't automatically translate to intact-skin scenarios.

## What is the regulatory status of GHK-Cu and GLOW?

Topical copper tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient in the US, EU, and UK with a long safety record in that form. Injectable or systemic GHK-Cu has no approved therapeutic indication. GLOW and its injectable constituents are not approved by the FDA, EMA, or any other major regulatory body. BPC-157 was identified by the FDA in 2023 as not eligible for pharmacy compounding pending further evaluation. TB-500 is classified as a non-approved substance under WADA's S2 category (peptide hormones, growth factors and mimetics), prohibited in sport at all times [8]. All injectable or systemic use of these compounds is research-only.

---

A literature desk for skin-peptide research — citations drawn from the peer-reviewed record, not a product and not a prescription.